Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca To Continue Collaboration With Shionogi On Crestor

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca CEO David Brennan stated Oct. 8 that the company will keep the same relationship with Japanese pharmaceutical company Shionogi, after Shionogi's purchase of American firm Sciele Pharma. Currently, AstraZeneca and Shionogi are collaborating in marketing hyperlipidemia drug Crestor (rosuvustatin). Brennan also disclosed that the company will keep the current staff level of 3,200 in Japan, amid its effort to cut work force and streamline operations in the U.S. and Europe. Shionogi launched the take over bid for Sciele in September and completed the bid Oct. 6 in an effort to strengthen the company's sales network in the U.S. market. (Click here for more - Japanese language) "AstraZeneca To Continue The Same Relationship With Shionogi - AstraZeneca CEO" - Nikkei Sangyo News (10/8/08)

You may also be interested in...



One Hundred Years Later, Eli Lilly And Shionogi Hold Onto Cross-Pacific Partnership

Indianapolis-based Eli Lilly has been able to maintain a partnership with Osaka-headquartered Shionogi for exactly one century. Their relationship started when Shionogi started importing gelatin capsules from Lilly back in 1909. Alliance managers from Lilly and Shionogi sat down with PharmAsia News' Tokyo bureau to talk about what has made the partnership so successful.

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel